NCT05361564 2022-05-04A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Yonsei UniversityPhase 2 Unknown12 enrolled